Patients with multiple myeloma requiring intensive care are experiencing improved survival rates, despite presenting with higher levels of illness severity at the time of admission. According to a retrospective cohort analysis published in Annals of Intensive Care, the adjusted one-year mortality for these patients dropped significantly between 2007 and 2023, with an adjusted hazard ratio of 0.68.
Why Are Survival Outcomes Improving for Myeloma Patients in the ICU?
Survival improvements are largely attributed to the evolution of both critical care medicine and modern myeloma-specific therapies. Researchers led by S. Nakaa evaluated 428 adult patients admitted to a single intensive care unit over a 17-year period. Despite the fact that patients admitted between 2016 and 2023 presented with higher Sequential Organ Failure Assessment (SOFA) scores—indicating more acute physiological stress—their long-term outcomes were better than those treated in the 2007–2015 cohort.
Which Factors Predict Mortality in the Modern Treatment Era?
Data from the study indicates that not all patients face the same risks. For those admitted between 2016 and 2023, two specific variables emerged as independent predictors of higher one-year mortality:
- Treatment History: Patients who had already received more than two lines of myeloma therapy before their ICU admission faced a 77% higher risk of mortality.
- Illness Severity: Higher SOFA scores at the time of admission remained a strong, independent predictor of poorer survival.
Interestingly, factors such as age, diabetes, and pre-existing performance status were not found to be independent predictors of mortality once researchers adjusted for other variables. Furthermore, high-risk cytogenetic disease did not independently dictate short-term ICU survival, suggesting that clinicians should avoid using these genetic markers as the sole basis for denying intensive care support.
How Should Clinical Practice Adapt to These Findings?
The findings emphasize the need for early intervention and coordinated care. The investigators suggest that patients who have not undergone extensive prior treatment are the most likely to see meaningful survival benefits from intensive care. Consequently, authors recommend that hematologists and intensivists collaborate closely during the early stages of a patient’s decline to ensure timely ICU referral.
Frequently Asked Questions
What was the overall mortality rate for multiple myeloma patients in the study?
Across the entire 17-year study period, the overall ICU mortality rate was 12.1%, hospital mortality was 21.7%, and one-year mortality was 40.6%.
Does having high-risk cytogenetics mean a patient shouldn’t go to the ICU?
No. The study found that high-risk cytogenetic features did not independently influence short-term ICU survival in the contemporary era, indicating these features should not be the sole criteria for admission decisions.
What is the most common reason for ICU admission in this population?
Acute respiratory failure remains the primary reason for ICU admission for patients with multiple myeloma.
For more insights on advances in hematological care, subscribe to our clinical updates newsletter or explore our oncology research archive. Have questions about these findings? Leave a comment below to join the discussion.
